This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
With the upcoming approval of the first medications targeting NASH (non-alcoholic steatohepatitis) patients, the market value is predicted to reach over US$7.5bn by 2025. Our latest infographic reveals more information about the current drugs in development and the estimated increase in sales that will occur over the next few years.